If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro ® (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Is Mounjaro® (tirzepatide) available as an oral formulation?
Tirzepatide is not available in pill form for oral administration. Tirzepatide is an injectable medicine for subcutaneous use. It comes as a liquid solution in single-dose, prefilled pens.
See important safety information, including boxed warning, in the attached prescribing information.
Tirzepatide Formulation
Tirzepatide is not available in pill form for oral administration.1
Tirzepatide is an injectable medicine for subcutaneous use. It contains tirzepatide, a once weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.1
Tirzepatide injection is a clear, colorless to slightly yellow, sterile, preservative-free solution.1
Each single-dose pen contains a 0.5 mL solution of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide and the following excipients: sodium chloride (4.1 mg), sodium phosphate dibasic heptahydrate (0.7 mg), and water for injection.1
Enclosed Prescribing Information
Reference
1Mounjaro [package insert]. Indianapolis, IN: Eli Lilly and Company; 2023.
Date of Last Review: August 11, 2023